Fellowships

Wei Z Ai, MD, PhD; Stanford University School of Medicine, Stanford, CA
"Combined intratumoral injection of CpG 7909 and radiation for low-grade lymphoma"

Zaid Al-Kadhimi, MD; Beckman Research Institute of the City of Hope, Duarte, CA
"Strategies to improve trafficking and activation of genetically modified T-cells"

Christine Bonzon, PhD; David Geffen School of Medicine, UCLA, Los Angeles, CA
"TCL1 Regulation in the pathogenesis of germinal center B-cell lymphomas"

Annie Bourdeau, PhD; McGill University, Quebec, Montreal, Quebec 
"Regulation of lymphomagenesis by protein tyrosine posphatases:  PTP1B and TC-PTP"

Greg Coffey, PhD; Stanford University, Stanford, CA 
"Hepatitis C virus-induced B Cell lymphomagenesis"

Irene M. Ghobrial, MD; Dana-Farber Cancer Institute, Boston, MA
"Role of the P13K pathway in non-Hodgkin lymphoma"

John F. Kurland, PhD; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 
"Role of conserved elements and novel interacting proteins in MYC-induced lymphomagenesis"

Hudan Liu, PhD; The Trustees of the University of Pennsylvania, Philadelphia, PA
"Functional analysis of Notch transcriptional targets in T-ALL"

Alice Nemajerova, PhD; The Research Foundation of SUNY-SUNY at Stony Brook, Stony Brook, NY
"The role of p73 in B-cell lymphomagenesis"

Patrick Ng, PhD; Stanford University School of Medicine, Stanford, CA
"Idiotype ScFv fusion protein vaccines for the Treatment of B-cell lymphoma"

Maria Corinna Palanca-Wessels, MD, PhD; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
"Optimizing delivery of short interfering RNA (siRNA) for the treatment of non-Hodgkin lymphoma"

Steven Park, MD; Fred Hutchinson Cancer Research Center, Seattle, WA
"Pretargeted anti-CD20 radioimmunotherapy with streptavidin mutants-bisbiotin binding system"

Hong Qin, MD, PhD; The University of Texas, MD Anderson Cancer Center, Houston, TX 
"Translational development of chemokine-fused lymphoma idiotype DNA vaccine"

Ramune Reliene, PhD; University of California, Los Angeles, CA
"Chemoprevention of genetic instability and lymphomagenesis in ATM mutant mice"

Frank Rosenbauer, PhD; Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany
"Molecular pathogenesis of T-cell lymphomas induced by deletion of a PU.1 gene cis-element"

Jia Ruan, MD, PhD; Weill Medical College of Cornell University, New York, NY 
"Lymphoma neo-angiogenesis and anti-angiogenic therapy"

Vishva Sharma, PhD; University of Massachusetts Medical School, Worcester, MA 
"Identification of notch-1 target genes in T-ALL"

Christian Steidl, MD; British Columbia Cancer Agency, Vancouver, BC
"Predicting treatment response in Hodgkin lymphoma by identifying new molecular markers"

Jan van Riggelen, PhD; Stanford University, Stanford, CA 
"Mechanism of tumor regression upon MYC onocogene inactivation in a lymphoma mouse model"

Irina Velichutina, PhD; Albert Einstein College of Medicine, Bronx, NY 
"PcG as a therapeutic target in diffuse large B-cell lymphomas"

Irina A. Vlasova, MD, PhD; University of Minnesota, Minneapolis, MN 
"Abnormal messenger RNA stability in malignant T-cells"

Jing Yang, PhD; University of Texas, MD Anderson Cancer Center, Houston, TX
"Targeting beta2-microglobulin for induction of tumor apoptosis in mantle cell lymphoma"

Qinyan Yin, PhD, DVM; Tulane University Health Sciences Center, New Orleans, LA
"Development of EBNA 1 siRNAs as potential therapeutics for EBV associated lymphomas"

Johannes Zakrzewski, MD; Memorial Sloan-Kettering Cancer Institute, New York, NY 
"Novel strategies to enhance T-cell reconstitution after hematopoietic stem cell transplantation"

Jing Zhou, MD, PhD; The Wistar Institute, Philadelphia, PA
"Mechanism of DNA replication and plasmid maintenance of epstein-barr virus (EBV)"

Clinical Investigator Career Development Awards

Joshua D. Brody, MD; Stanford University School of Medicine, Stanford, CA
"Dendritic cell-idiotype vaccine for mantle cell NHL after autologous stem cell transplant"

Damian J. Green, MD; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
"Optimizing radioimmunotherapy of lymphoma"

Ann S. LaCasce, MD; Dana-Farber Cancer Institute, Boston, MA
"Targeting NF-kB in mediastinial Large B-cell lymphoma"

John M. Pagel, MD, PhD; Fred Hutchinson Cancer Research Center, Seattle, WA
"Pretargeted radioimmunotherapy for CD20+ non-Hodgkin lymphoma"

Brian Till, MD; Fred Hutchinson cancer Research Center, Seattle, WA
"Adoptive immunotherapy with CD20-specific T-cells for indolent and mantle cell lymphoma"

CLL-SLL Research Grant

David A. Frank, MD, PhD; Dana-Farber Cancer Institute, Boston, MA
"Targeted activation of STAT1 for the molecular therapy of chronic lymphomcytic leukemia"

Tracy M. Handel, PhD; University of California, San Diego, CA
"SDF1 in CLL survival and aggressiveness; interruption of  signaling as a therapeutic strategy"

Follicular Research Grant

Steven H. Bernstein, MD; James P. Wilmot Cancer Center, University of Rochester, Rochester, NY
"Rituximab elicitation of tumor specific T-cell responses in follicular lymphoma patients"

Laurence J.N. Cooper, MD, PhD; MD Anderson Cancer Center, University of Texas, Houston, TX
"Second-generation trial for follicular lymphoma using CD19-specific T-cells"

Sandra J. Horning, MD; Stanford University Medical Center, Stanford, CA
"Identification of biomarkers in follicular lymphoma"

Anne J. Novak, PhD; Mayo Clinic College of Medicine, Rochester, MN
"Biology and epidemiology of BlyS and APRIL in follicular lymphoma"

Mantle Cell Correlative Awards

Thomas M. Habermann, MD; Mayo Clinic College of Medicine, Rochester, MN
"Genetic predictors of prognosis in mantle cell lymphoma"

Ronald Levy, MD; Stanford University, Stanford, CA
"BCR signal transduction in mantle cell lymphoma patients receiving a Syk Kinase inhibitor"

Christiane Pott, MD; University Hospital Schleswig-Holstein, Kiel, Germany
"Minimal Residual Disease (MRD): Optimization and Validation of Quantification Techniques"

Geoffrey I. Shapiro, MD, PhD; Dana-Farber Cancer Institute, Boston, MA
"Pharmacodynamic studies of flavopiridol and PDO332991 in mantle cell lymphoma"

Wendy Stock, MD; The University of Chicago, Chicago, IL
"Strategies to eradicate minimal residual disease in mantle cell lymphoma"

Mantle Cell Awards

Robert Baiocchi, MD, PhD; The Ohio State University, Columbus, OH
"Targeting HDAC and protein arginine methyltransferase 5 enzymes in mantle cell lymphoma"

Steven H. Bernstein, MD; James P. Wilmot Cancer Center, University of Rochester, Rochester, NY
"Triterpenoids as novel therapeutic agents for the treatment of mantle cell lymphoma"

Joseph Bertino, MD;  The Cancer Institute of New Jersey, New Brunswick, NJ
"Successful expansion of umbilical cord blood stem cells"

Tulin Budak-Alpdogan, MD and Joseph Bertino MD; The Cancer Institute of New Jersey, New Brunswick, NJ
"Post-transplant high dose MTX/ARA-C consolidation: A drug resistance gene transfer strategy for myeloprotection"

Elias Campo, MD, University of Barcelona, Barcelona, Spain
and Andreas Rosenwald, MD; University of Wuerzburg, Germany
"Molecular mechanisms associated with clinical progression and drug resistance in MCL"

Richard E. Champlin, MD; MD Anderson Cancer Center, Houston TX
"Separation of graft vs lymphoma from graft vs host disease using antithird party cytolic t-cell for treatment of MCL"

Sophie Dessureault, MD, PhD; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
"A phase one trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease"

Johannes Drach, MD; University Hospital Vienna, Austria
"Growth control of mantle cell lymphoma by the addition of thalidomide to standard treatment"

Martin Dreyling, MD, PhD; University Hospital Grosshadern/LMU, Munich, Germany
"European MCL network:  molecular targeted treatment options and individual patient risk factors"

Martin Dreyling, PD, MD; University Hospital Grosshadern/LMU Munich, Germany
"Evaluation of new therapeutic options and identification of molecular risk factor"

Elliot Epner, MD, PhD; Oregon Health and Science University, Portland, OR
"Turning cyclin D1 on and off in mantle cell lymphoma"

Richard J. Ford, MD, PhD; MD Anderson Cancer Center, Houston TX
"Molecular and biological approaches for targeting new therapies in MCL"

Stephen J. Forman, MD; City of Hope Medical Center, Duarte, CA
"Targeting minimal disease after autologous hematopoietic stem-cell transplant for mantle cell lymphoma by adoptive transfer of CD-19-specific T cells"

Randy D. Gascoyne, MD, FRCPC; British Columbia Cancer Agency, Vancouver, British Columbia, Canada
"New molecular targets in mantle cell lymphoma"

Ajay K. Gopal, MD; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
"Anti-CD45 radioimmunotherapy for mantle cell lymphoma"

Ajay K. Gopal, MD; The University of Washington, Seattle, WA
 "High-dose radioimmunotherapy transplant conditioning regimens for relapsed or refractory MCL"

Timothy C. Greiner, MD; University of Nebraska Medical Center, Omaha, NE
"Methylation analysis in an international group of mantle cell lymphomas"

Timothy C. Greiner, MD; University of Nebraska Medical Center, Omaha, NE
"Methylation analysis in mantle cell lymphoma using an oligonucleotide microarray"

Pedro Jares, PhD; IDIBAPS, University of Barcelona, Barcelona, Spain
"Identification of tumor suppressor genes, epigenetic portrait, and genotyping of mantle cell lymphoma"

Shantaram Joshi, PhD; University of Nebraska Medical Center, Omaha, NE
"Optimizing dendritic cell-based therapy for mantle cell lymphoma"

Issa Khouri, MD; MD Anderson Cancer Center, Houston TX
"Allogeneic stem cell with Rituximab-containing nonablative conditioning regimen for advanced/recurrent MCL".

John P. Leonard, MD; Weill Medical College of Cornell University, New York, NY
"Angiogenesis and anti-angiogenic therapy in MCL".
      
Timothy W. McKeithan, MD, PhD and John Chan, MD; University of Nebraska Medical Center, Omaha, NE
"Screening with siRNA libraries to identify potential therapeutic targets for MCL"

Shigeki Miyamoto, PhD; University of Wisconsin School of Medicine and Public Health, Madison, WI
"Targeting NF-kB activation mechanisms for MCL drug development"

Oliver W. Press, MD, PhD; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
"Optimizing adoptive T-cell immunotherapy for mantle cell lymphoma"

Leticia Quintanilla-Martinez, MD; Institute of Pathology, GSF Research Center for Environment and Health, Oberschleissheim,  Germany
"Relevance of cyclin D1 isoforms expression for the pathogenesis of mantle cell lymphoma (MCL)"

Louis M Staudt, MD, PhD; National Cancer Institute, Bethesda, MD
"Identification of therapeutic targets in mantle cell lymphoma using an RNA interference library screen"